Advances in Therapy

, Volume 19, Issue 2, pp 91–97 | Cite as

Brimonidine .2% as a replacement for beta blockers in geriatric patients with glaucoma

  • Robert J. Noecker
  • Study Group for the Efficacy of Brimonidine in Geriatric Patients


This 3-month multicenter, open-label study of 89 geriatric patients with glaucoma evaluated the substitution of brimonidine twice daily for topical beta blockers that had been used for at least 6 months. The primary outcome measures were reduction in intraocular pressure (IOP) from baseline at 2 hours postdose, change in cardiac and respiratory function, quality of life, and patient satisfaction. Patients were queried about adverse events at each visit and completed a quality-of-life questionnaire at the final evaluation. In this cohort with a mean age of 75.4 years, the average duration of topical beta-blocker therapy was 5 years. Brimonidine twice daily produced an additional mean reduction in IOP of 8.2% (1.4 mm Hg;P < .001). Eighty-eight percent of patients (60/68) reported being at least as satisfied with brimonidine as with their previous beta-blocker regimen, and 46% (31/68) reported greater satisfaction with brimonidine. Additionally, 40% of patients (27/68) noted increased energy after the switch, and 43% (29/68) described brimonidine as more soothing than topical beta blockers. In this elderly population, the replacement of topical beta blockers with brimonidine twice daily significantly decreased IOP, improved quality of life, and enhanced patient satisfaction.


glaucoma elderly brimonidine topical beta blockers 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Quillen DA. Common causes of vision loss in elderly patients.Am Fam Physician. 1999;60:99–108.PubMedGoogle Scholar
  2. 2.
    Kobelt G. Comparative data for all countries. In Jonsson B, Krieglstein G, eds.Primary Open-Angle Glaucoma: Differences in International Treatment Patterns and Costs. Oxford: Isis Medical Media; 1998:16–26.Google Scholar
  3. 3.
    Zimmerman T. Medicinal therapy for glaucoma. In: Eid TM, Spaeth GL, eds.The Glaucomas: Concepts and Fundamentals. Philadelphia: Lippincott-Williams & Wilkins; 2000:227–245.Google Scholar
  4. 4.
    Melamed S, David R. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results.Clin Ther. 2000;22:103–111.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee DA. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension.Clin Ther. 2000;22:53–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial.J Ocul Pharmacol Ther. 2000;16:3–18.PubMedCrossRefGoogle Scholar
  7. 7.
    McMahon CD, Shaffer RN, Hoskins HD, Bachorik PS, Quigley HA. Adverse effects experienced by patients taking timolol.Am J Ophthalmol. 1979;88:736–738.PubMedGoogle Scholar
  8. 8.
    Jones FL, Ekberg NG. Exacerbation of asthma by timolol.N Engl J Med. 1979;301:270.PubMedGoogle Scholar
  9. 9.
    Schocken DD, Roth GS. Reduced beta adrenergic receptor concentration in aging man.Nature. 1977;267:856–858.PubMedCrossRefGoogle Scholar
  10. 10.
    Nijkamp FP, Engels F, Hendricks PAJ. Mechanisms of beta adrenergic receptor regulation in lungs and its implications for physiological responses.Physiol Rev. 1992;72:323–326.PubMedGoogle Scholar
  11. 11.
    Vestal RE, Alastair JJ, Wood MB, Shand MB. Reduced beta adrenergic receptor sensitivity in the elderly.Clin Pharmacol Ther. 1979;26:181–186.PubMedGoogle Scholar
  12. 12.
    Cheung DC, Timmers MC, Zwinderman AH. Long-term effects of a long-acting beta-2 adrenoreceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.N Engl J Med. 1992;327:1198–1203.PubMedCrossRefGoogle Scholar
  13. 13.
    Diggory P, Franks W. Medical treatment of glaucoma-a reappraisal of the risks.Br J Ophthalmol. 1996;80:85–89.PubMedCrossRefGoogle Scholar
  14. 14.
    Bogner WP III. Short-term escape and long-term drift, the dissipation effects of the beta adrenergic blocking agents.Surv Ophthalmol. 1983;38:235–240.CrossRefGoogle Scholar

Copyright information

© Health Communications Inc 2002

Authors and Affiliations

  • Robert J. Noecker
    • 1
  • Study Group for the Efficacy of Brimonidine in Geriatric Patients
  1. 1.Department of OphthalmologyUniversity of ArizonaTucson

Personalised recommendations